Quest Diagnostics upgraded to strong buy after Q3 beat
Alpha Vantage · Seeking Alpha · · AI-summarised by FinFlash
Quest Diagnostics has been upgraded to a strong buy after its fourth consecutive earnings beat, with Q3 revenue up 10% year-over-year and EPS rising 28.7%. The company also announced a new Alzheimer's test, reinforcing its competitive edge through innovation, strong margins and an investment-grade balance sheet. Analysts see the stock as a solid pick for dividend growth and capital appreciation.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.